Cadence Pharmaceuticals, Inc. (CADX)
Q2 2012 Earnings Call
August 2, 2012, 04:30 pm ET
Ted Schroeder - President & CEO
Bill LaRue - SVP & CFO
Jim Breitmeyer - EVP & CMO
Scott Byrd - SVP & Chief Commercial Officer
Charles Duncan - JMP Securities
Richard Lau - Wedbush Securities
Imran Babar - Cowen
Michael Schmidt - Leerink Swann
Patti Bank - DISCERN Securities
Juan Sanchez - Ladenburg
Greg Fraser - Bank of America
Good afternoon and welcome to the Cadence Pharmaceuticals second quarter 2012 financial results conference call. On the call today are Ted Schroeder, President and CEO, Bill LaRue, Senior Vice President and Chief Financial Officer, Jim Breitmeyer, Executive Vice President and Chief Medical Officer, and Scott Byrd, Senior Vice President and Chief Commercial Officer.
At this time, I would like to inform you that this conference is being recorded and that all participants are in a listen-only mode. At the request of the company, we will open the conference up for questions-and-answers after the management presentation.
Our first speaker is Bill LaRue. Go ahead, sir.
Thank you. Good afternoon everyone. Before we begin, I would like to remind you that statements included in this conference call that are not a description of historical facts are forward-looking statements. Forward-looking statements include statements regarding financial guidance, expectations regarding sales and demand, formulary approval, revenue growth, expenses and the market opportunity for OFIRMEV. The status of the recalls of OFIRMEV and related investigation, our expectation that no supply shortages will result from the July 2012 recall, knowing the cost of this recall have a material impact on our financial statements and the date on which we expect to commence enrollment in our post approval pediatric clinical trial of OFIRMEV. You are cautioned not to place undue reliance on these forward-looking statements which speak only as of the day that hereof.